



UK ONCOLOGY FORUM 2024

Doubletree by Hilton, Brighton

Thursday 13th & Friday 14th June 2024

FINAL PROGRAMME

This meeting is for UK Oncology NHS Healthcare Professionals ONLY

The UK Oncology Forum programme has been wholly designed by the UK Oncology Forum Faculty and session chairs. No sponsors have had any input in to the UKOF programme or the speaker/expert choices. The faculty, chairs, and speakers of the UKOF have had no input or influence over Industry symposia. The UK Oncology Forum is ABPI & RCP compliant. CME will NOT be awarded to all industry symposiums. All HCPs must attend the required sessions to qualify for CME certificates of attendance. PATIENTS AND MEMBERS OF THE PUBLIC CANNOT ATTEND, due to ABPI code, compliance, and guidelines.

Industry Symposia will **NOT** be run parallel to the UKOF programme.

To receive your certificate of attendance for CPD points:

- You must attend clinical sessions on both days
- You must attend the keynote opening and closing sessions

DAY ONE – THURSDAY 13TH JUNE 2024

*Additional refreshment breaks in the Exhibition Hall Cambridge & Durham to be added and further details to follow.

TIME	SUBJECT		
08:30hrs ~ 12:00hrs	UKECRC Executive Committee Meeting (closed meeting) – Gloucester Meeting Room		
10:00hrs ~ 12:00hrs	IOCN The Immuno-Oncology Clinical Network – Edinburgh Meeting Room		
10:00hrs ~ 12:00hrs	NOTCH AGM – Sandringham Meeting Room		
11:00hrs ~ 12:00hrs	UKOMiC Committee Meeting – Oxford Gallery		
10:45hrs ~ 11:45hrs	National Cancer Alliance Brainstorming Meeting – Osbourne Suite Co-Chaired by Dr Helen Winters-SWAG, Paul Thomas-NEL & Representative-WY&HCA		
10:00hrs ~ 12:00hrs	UKONS–Launch of the multi-disciplinary Acute Oncology Competence Assessment Passports – Chair Verna Lavender (all welcome) Ambassador Meeting Room		
	1000 - 1005	Welcome and Introduction	Verna Lavender
	1005 - 1015	Standardising Acute Oncology Education, Training and Assessment	Verna Lavender
	1015 – 1030	Development of the AO Competence Assessment Passports	Gina Madera
	1030 – 1045	Review of the Macmillan AO Online Course and Development of the Level 1 Passport	Leigh Hamilton
	1045 - 1100	Pilot of the AO Passport Across the UK	Gina Madera
	1100 - 1130	Pilot Evaluation	Verna Lavender
	1130 - 1140	Revision of AO Competence Assessment Documentation and Recommendations	Gina Madera
	1140 – 1155	Q&A - Panel	All
	1200	Close	
11:00hrs ~ 12:00hrs	SIOG UK (Closed Committee Meeting) – Lancaster Meeting Room		
10:30hrs ~ 11:30hrs	AMGEN SYMPOSIUM – Kensington Meeting Room An evolution of XGEVA (denosumab): from vial to pre-filled syringe, from hospital to home self-administration Speakers: Dr John Conibear, Dr Caroline Wilson, Dr Naomi Farrington, Mr Nicholas Goodger		
10:30hrs ~ 11:10hrs	SCIENSUS SYMPOSIUM – Balmoral Meeting Room Empowering Oncology Care: Harnessing Patient Reported Data and Insights to Transform the Patient Experience Speaker: Professor Chris Nutting		

TIME	SUBJECT	
11:45hrs ~ 12:45hrs	NOVARTIS DIAMOND SPONSOR BREAST SYMPOSIUM – Clarence Meeting Room (lunch provided) Service Redesign: How can non-medical prescribing and innovation scale the SACT Clinic of the Future? Speakers: Chair: Dr Kyle Crawford, Dr Catherine Oakley, Claire Goldrick and Emma Morris	
12:00hrs ~ 12:55hrs	LUNCH & REFERESHMENTS IN EXHIBITION HALL CAMBRIDGE & DURHAM (PLEASE VISIT THE STANDS)	
13:00hrs ~ 13:05hrs	UKOF OPENS ~ WELCOME & INTRODUCTION – CHAIR: PROFESSOR RUTH PLUMMER MBE- Oxford Meeting Room – Main Plenary	
13:05hrs ~ 14:00hrs	OPENING KEYNOTE SPEAKER – Professor Marnix Jansen Digital Pathology and Artificial Intelligence... more to come! Oxford Meeting Room – Main Plenary	
14:00hrs ~ 14:25hrs	REFRESHMENT BREAK IN EXHIBITION HALL CAMBRIDGE & DURHAM	
14:30hrs ~ 17:25hrs	BREAST BREAKOUT – CHAIR: Dr Marina Parton – Clarence Meeting Room	
	Changing practice/challenging perspectives; A sweep through recent breast cancer data and what is relevant in the clinic from the major conferences ASCO, ESMO and SABCS. This session will end with a round table open discussion of what the speakers are already carrying over into their clinic. We will also focus on disparities in breast cancer treatment and outcomes with experts in the field-how people access the care (including trials), variation between different socio-economic groups, geographical disparities in the UK. We explore potential strategies both nationally and in the clinic, the use of real world data (RWD)	
	1430-1435	Welcome and introduction Dr Marina Parton
	Conference updates: what you need to know in the clinic (and a bit more)	
	1435-1455	Early stage breast cancer ASCO updates Dr Alistair Ring
	1455-1515	Anticipating advances in Metastatic Breast Cancer in 2024: a conference update Dr Vasileios Angelis
	1515-1525	Round table discussion/questions: Does this change my practice on Monday? All Speakers
	1525-1540	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS) All
	Special focus: disparities in cancer treatment and outcomes	
	1540-1605	Equal care for every age: addressing disparities in breast cancer management for older adults Dr Nicolo Matteo Luca Battisti
	1605-1625	Does “postcode lottery” to care in the UK still exist? National and local approaches Professor Richard Simcock
	1625-1645	Ethnicity and breast cancer Dr Toral Gathani
	1645- 1705	Round table discussion/questions ; Take homes for the clinic on Monday (I am so busy already...)? All Speakers

	1705-1720	Moving forward to more equal care	Ms Sarah Adomah
	1720-1725	Summary & Closure	Dr Marina Parton
14:30hrs ~ 17:25hrs	COLORECTAL BREAKOUT – CHAIR: Professor Vicky Coyle – Kensington Meeting Room		
	Colorectal cancer – current management and future perspectives. Improved molecular characterisation and staging of colorectal cancers have identified patient subgroups where targeted therapies and/or multidisciplinary approaches to management of locally advanced or advanced disease have a role in potentially achieving long-term control of disease and improved outcomes. In this session, speakers will use cases to discuss current and emerging systemic therapies and multidisciplinary management of peritoneal metastatic disease. The session will also include updates in CRC management from ASCO 2024 and other conferences.		
	1430-1435	Welcome and introduction	Professor Vicky Coyle
	1435-1505	Multidisciplinary management of peritoneal disease	Mr Michael Braun
	1505-1535	Multi-modal and multi-disciplinary approach in the light of evidence improves outcomes	Dr Khurum Khan
	1535-1555	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1555-1625	Updates in systemic therapies for advanced CRC	Dr Alice Dewdney
	1625-1655	What is the role of surgery for patients with dMMR/MSI-High CRC? An oncologist's point of view	Dr Kai-Keen Shiu
	1655-1720	Panel Q and A session	All
	1720-1725	Summary & Closure	Professor Vicky Coyle
14:30hrs ~ 17:15hrs	GYNAE BREAKOUT – CHAIR: Dr Patricia Roxburgh – Lancaster Meeting Room		
	Understand the risks and benefits of robotic surgery in management of gynaecological cancer. To increase awareness of the symptom burden that menopause causes for patients with gynaecological cancers. To make gynaecologic cancer teams aware of resources available to guide menopause management in cancer patients. To understand the role of immunotherapy and anti-body drug conjugates in the management of metastatic cervical cancer. To know how to manage inoperable, ovarian cancer associated malignant bowel obstruction		
	1430-1435	Welcome and introduction	Dr Patricia Roxburgh
	1435-1500	Managing menopause in patients with Gynaecological cancers	Dr Rebecca Bowen
	1500-1525	Advances in management of metastatic cervical cancer	Dr Nelleke Ottevanger
	1525-1550	Non-surgical management of malignant bowel obstruction in advanced ovarian cancer	Professor Agnieszka Michael
	1550-1615	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All

	1615-1640	Role of robotic surgery in management of gynaecological cancers	Professor Jayanta Chatterjee
	1640-1705	Panel Q and A session	All
	1705-1715	Summary & Closure	Dr Patricia Roxburgh
14:30hrs ~ 17:35hrs	LUNG BREAKOUT – CHAIR: Professor Samreen Ahmed – Balmoral Meeting Room		
	Please come and learn from key opinion leaders in real life MDT setting about managing early stage lung cancer. This is a new and evolving area of curative treatment for our lung cancer patients. This is then combined with practice changing studies presented in the last year and hot off the press from ASCO in both lung cancer and mesothelioma. We also have the latest in the minefield that is EGFR driven lung cancer and the latest in liquid biopsies and its application.		
	1430-1435	Welcome and introduction	Professor Samreen Ahmed
	1435-1540	Stage 1-3 Early NSCLC MDT Approach	Moderated - Prof Samreen Ahmed Surgeon - Mr Michael Shackcloth Clinical Oncologist - Dr Fiona McDonald Medical Oncologist - Dr Tom Newsom-Davis Respiratory Physician – Prof Emma O’Dowd
	1540-1600	ASCO Lung cancer highlights	Dr Tom Newsom-Davis
	1600-1615	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	
	1615-1640	Developments in EGFR Mutated NSCLC	Dr Anna Minchom
	1640-1700	Liquid Biopsy: Are tissues biopsies obsolete? Pilot/Graill updates	Dr Nirupa Murugaesu
	1700-1720	Developments in surgery/SACT in mesothelioma	Dr Riyaz Shah
	1720-1730	Panel Q and A session	All
	1730-1735	Summary & Closure	Professor Samreen Ahmed
14:30hrs ~ 17:30hrs	MELANOMA BREAKOUT – CHAIR: Dr Pippa Corrie - Osbourne Suite		
	Multidisciplinary challenges for modern melanoma clinical practice As melanoma clinical practice continues to evolve apace, this session will review the real-world impact of surgical and oncological interventions for early-stage melanoma patients. Specific challenges for managing very young patients diagnosed with melanoma and new surveillance guidelines for ocular melanoma will be discussed. Finally, an update on new melanoma vaccines being tested in clinical trials will be provided.		
	1430-1435	Welcome and introduction	Dr Pippa Corrie

	1435-1510	Does adjuvant therapy impact survival?	Dr Hildur Helgadóttir
	1510-1540	Challenges of Sentinel lymph node biopsy in the real world	Mr Siva Kumar
	1540-1600	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1600-1630	Vaccines in early and advanced disease	Dr Heather Shaw
	1630-1700	Managing melanoma in children & young adults	Dr Aditi Vedi
	1700-1725	New Ocular melanoma surveillance guidelines	Dr Matthew Wheeler
	1725-1730	Panel Q and A session	All
	1730-1735	Summary & Closure	Dr Pippa Corrie
14:30hrs ~ 17:10hrs	PANCREATIC BREAKOUT – CHAIRS: Professor David Chang & Dr Fieke Froeling – Edinburgh Meeting Room		
	In this session four internationally renowned speakers will discuss a wide range of developments in the management of pancreatic malignancies. Professor Hanneke Wilmink will discuss state-of-the art, challenges and advances made in treatment of localised pancreatic cancer. Dr Bristi Basu will cover novel therapeutics and management of advanced pancreatic cancer. Dr Mairead McNamara will cover diagnosis, localised and systemic treatments of pancreatic neuroendocrine tumours. Professor Keith Roberts will put recent treatment advances in perspective, review best practice currently and how optimising standard of care approaches can result in better patient outcomes.		
	1430-1435	Welcome and introduction	Professor David Chang & Dr Fieke Froeling
	1435-1505	Perioperative treatment of pancreatic cancer	Prof Dr Hanneke Wilmink
	1505-1535	Drug development for advanced pancreatic cancer, ASCO update	Dr Bristi Basu
	1535-1545	Panel Q and A session	All
	1545-1555	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1555-1625	PERT – as effective as chemotherapy or surgery in pancreatic cancer treatment?	Prof Keith Roberts
	1625-1655	Treatment of pancreatic neuroendocrine tumours	Dr Mairead McNamara
	1655-1700	Panel Q and A session	ALL
	1700-1710	Summary & Closure	Professor David Chang & Dr Fieke Froeling
14:30hrs ~ 17:20hrs	PROSTATE BREAKOUT – CHAIR: Professor Nick Van As – Ambassador Meeting Room		
	<p>“What is hot and what is not in prostate cancer”</p> <p>Prostate cancer treatment has evolved significantly over the last decade, with developments across the entire treatment spectrum from improvement in surgery, transformation in radiotherapy technology and hugely significant improvements in systemic therapy, the landscape is</p>		

	unrecognisable from 10 years ago. The session will focus on “What his hot and what is not” in surgery, radiotherapy for localised disease and metastatic disease and systemic therapy.	
1430-1435	Welcome and introduction	Prof Nick Van As
1435-1505	Mets directed therapy	Prof Piet Ost
1505-1510	Panel Q and A session	All
1510-1540	Localised Disease	Dr Alison Tree
1540-1545	Panel Q and A session	All
1545-1600	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
1600-1630	Is ‘3’ really the magic number?	Dr Alison Reid
1630-1635	Panel Q and A session	All
1635-1705	Surgical view	Mr Philip Charlesworth
1705-1710	Panel Q and A session	All
1710-1720	Summary & Closure	Prof Nick Van As

14:30hrs ~ 17:20hrs RAPID DIAGNOSTIC BREAKOUT – CHAIR: Dr Saoirse Dolly – Sandringham Meeting Room

At this year’s Non site specific (NSS) symposium at the Oncology forum we are excited to discuss current hot topics – effective service development and utilising novel technologies to drive earlier and faster cancer diagnosis and improved patient outcomes.

We will start with two evaluations of Rapid Diagnostics Clinics (RDC). Beth Russell and Geraint Jones will present the South East London expansion evaluation; providing their recommendations around workforce, RDC clinical models, patient experience and equity. We are very excited to have Elizabeth Maclean and Rachel Burkitt present the finding of the national RDC evaluation hot off the press. The national evaluation focuses on patient experience, optimal NSS pathway delivery, sequencing of testing and an economic evaluation.

The second session analyses novel diagnostics that may stratify that are being developed to aid faster and earlier cancer diagnosis. Richard Lee will give an update on the RDC Biomarker Study (RDC Bio) a groundbreaking study looking to identify high risk groups. This is using symptom profiling, clinical and imaging data and blood and other biomarker tools. Ms Carla Brackstone will give an overview of a novel AI technology for mammography. Thereafter, we will discuss one of the largest trials to date using a multi-cancer early detection (MCED) test - the NHS Galleri trial. Professor Lennard Lee will talk us through the progress of the trial as it nears completion this Summer. Trial manager, Ian Lowenhoff, will outline the optimal pathways to progress participants from the trial into the NHS for diagnostic work up. The session will conclude

	with a round table discussion looking at key learnings from the last three years of the trial which will help support development of the implementation pilot.	
1430-1435	Welcome and introduction	Dr Saoirse Dolly
Session 1: Evaluations of Non-site-specific services		
1430-1455	Evaluation of the expansion of non-site-specific services in South East London	Dr Beth Russell (Kings College London) & Geraint Jones (South East London Cancer Alliance)
1455-1520	First reports of the national Rapid Diagnostic Centres evaluation	Elizabeth Maclean (NHS England) & Rachel Burkitt (Ipsos Mori)
1520-1530	Panel Q and A session	All
1530-1545	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
Session 2: Novel diagnostics		
1545-1600	Updates on the RDC-Bio study	Dr Richard Lee (Royal Marsden Hospital)
1600-1615	AI in Breast Screening - Introduction to Mia (Mammography Intelligent Assessment)	Carla Brackstone (Kheiron Medical Technologies)
1615-1620	A (re)introduction to the NHS Galleri trial and overview of Multi-Cancer Bloods Tests	Professor Lennard Lee (NHSE)
1620-1640	Clinical referral to the NHS following a multi-cancer early detection (MCED) test result in the NHS-Galleri trial	Ian Lowenhoff (Queen Mary University of London)
1640-1715	Round table discussion on real world implementation of MCED tests	Professor Lennard Lee (NHSE) Rebecca Duggan (Northern Care Alliance) Geraint Jones (South East London Cancer Alliance) Ian Lowenhoff (Queen Mary University of London)
1715-1720	Summary & Closure	Dr Saoirse Dolly
14:30hrs ~ 17:10hrs	RENAL BREAKOUT – CHAIR: Dr Lisa Pickering – Gloucester Meeting Room	
A panel of renal cancer specialists will go through current best practice and review the latest and emerging data for systemic therapy and radiotherapy in both early stage and metastatic renal carcinoma. All illustrated by a range of clinical cases.		
1430-1435	Welcome and introduction	Dr Lisa Pickering
1435-1500	Adjuvant and upfront therapy: can we make sense of the conflicting data?	Prof James Larkin

	1500–1550	First line treatment of advanced renal cancer: All the conundrums and hopefully all the answers!	Dr Sarah Rudman & Dr Tom Waddell
	1550–1610	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1610–1635	What is the role of radiotherapy in renal cancer in 2024? – Not as radioresistant as we all thought	Dr Harshani Green
	1635–1700	Treatment beyond first line: What's the latest evidence after you've used immunotherapy?	Dr Lisa Pickering
	1700–1710	Summary & Closure	Dr Lisa Pickering
14:30hrs ~ 17:15hrs	TREATING THE OLDER CANCER PATIENT BREAKOUT – CHAIR: Prof Kwok-Leung Cheung – Buckingham Meeting Room		
	The majority of cancers occur in older adults. With the growing ageing population, it is important that we provide optimal care and treatment for these patients. This session will cover a multidisciplinary approach in the clinical management of this problem, from the perspectives of oncology and geriatrics. Our panel consists of both disciplines and, for the first time, will include our formal collaboration with oncology pharmacy. The session is designed and run by the UK Country Group of the International Society of Geriatric Oncology.		
	1430–1435	Welcome and introduction	Professor Kwok-Leung Cheung
	1435–1500	Geriatric oncology trials and ASCO updates	Dr Vèrène Dougoud
	1500–1515	De-prescribing (Joint session with British Oncology Pharmacy Association (BOPA))	Vanya Slavova-Boneva
	1515–1530	Panel Q and A session	All
	1530–1545	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1545–1600	National frailty guidelines	Dr Mark Baxter
	1600–1645	MDT case discussion	Geriatrician: Dr Rebecca Winter Advance Nurse Practitioner: Sarah Compton Occupational therapist: Katie Emblen-Jarrett Physiotherapist: Hannah Furness Dietitian: Megan Pattwell Pharmacist: Vanya Slavova-Boneva Oncologists: Dr Helen Winter and Dr Dougoud Surgeon: Professor Cheung

	1645–1700	Geriatric oncology as an unmet workforce training need in the UK	Professor Kwok-Leung Cheung
	1700–1710	Panel Q and A session	All
	1710–1715	Summary and closure	Professor Kwok-Leung Cheung
14:30hrs ~ 17:10hrs	RESEARCH UPDATES IN ORAL CARE UKOMIC BREAKOUT – CHAIR: Dr Charles Kelly - Surrey 2 Meeting Room		
	This session will be an opportunity to explore recent research and updates on addressing oral toxicities within the cancer setting. This session is aimed at doctors, nurses, dentists, pharmacists, and other health care professionals working in hospital and community care settings		
	1430–1435	Welcome and introduction	Dr Charles Kelly
	1435–1530	Dental Care in Patients with Head & Neck Cancer	Dr Ciaran Moore (Belfast, UK)
	1530–1535	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1535-1600	A Personal Story of Cancer	Karen Liesching-Schroder. Mouth Cancer Foundation
	1600-1635	An Intraoral Photo biomodulation Device for the Prevention of Oral Mucositis in Head and Neck Cancer Patients	Mike Cogswell, Magnet (Virtual – USA)
	1635-1655	Panel Q and A session	All
	1655-1710	Summary and closure	Dr Charles Kelly
17:30hrs – 17:45hrs	Novartis Product Talk – Clarence Meeting Room		
	HR+/HER2 – aBC: How the latest survival data can help to inform your choice of CDK4/6 inhibitor. Speaker: Dr Alistair Ring		

DAY TWO – FRIDAY 14TH JUNE 2024

TIME	SUBJECT		
08:00hrs ~ 08:45hrs	MERCK SERONO – SYMPOSIUM – Buckingham Meeting Room (breakfast included) Optimising the treatment experience for patients with urothelial carcinoma (UC) Speakers: Dr Giuseppe Banna & Dr Mark Prentice		
08:00hrs ~ 08:45hrs	MENARINI – BREAST SYMPOSIUM – Clarence Meeting Room Optimising endocrine-based therapy after CDK4/6 inhibitors in ER+/HER2- advanced breast cancer: emerging biomarkers and their role Speakers: Dr Mukesh Mukesh & Prof Samreen Ahmed		
08:00hrs ~ 08:45hrs	PIERRE FABRE- CRC SYMPOSIUM – Kensington Meeting Room (breakfast included) Practical Management of the BRAFv600E Mutant mCRC Patient: A Patient-Centric Approach Speakers: Professor Jenny Seligmann (Chair), Dr Gopalakrishnan Srinivasan & Ms Charlotte Durrant		
08:00hrs ~ 08:45hrs	PFIZER SYMPOSIUM – Balmoral Meeting Room (breakfast included) Beyond Randomised Controlled Trials: Demystifying the Role of Real-World Evidence Speakers: Prof Allan Hackshaw & Prof Geoff Hall *This symposium has been awarded in principle CPD certification, pending final certification retrospective to the event		
09:00hrs ~ 11:55hrs	ACUTE BREAKOUT – CHAIRS: Dr Anthony Cunliffe & Dr Caroline Wilson – Kensington Meeting Room		
	UKAOS Focus on Emergency Presentation of Cancer (Type I)		
	Session I: The Diagnostic Pathway		
	0900-0905	Welcome and introduction	Chair: Dr Anthony Cunliffe
	0905-0925	Emergency Presentation of Cancer: The national picture: Set the scene - National picture, national strategy, site specific differences, trajectory, and key messages. WHAT ABOUT DEVOLVED NATIONS	Dr Anthony Cunliffe
	0925-0945	Reducing ED presentation: A Primary Care perspective Opportunity & Obstacles: Current landscape - Referral pathways, challenges, interface with NSS How to manage the unwell suspected cancer – avoiding ED	Dr Abhijit Gill
	0945-1005	Emergency Presentation and SDEC opportunity: (Examples from Brain cancer & MSCC) Highlighting Brain & MSCC as potential SDEC opportunity – the role of VWs.	Dr Ragit Varia

		Brain Pathway & new MUO/MSCC & VW	
	1005-1020	Optimising Emergency Presentation of Lung Cancer Are there examples from site specific teams that capture good practice (SDEC/VW approach, optimised/virtual working), include early diagnosis (screening/biomarkers etc)	Dr Joanne Evans
	1020-1030	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
Session II: Treatment Decision-Making & Opportunity			
	1030-1035	Welcome back	Chair Dr Caroline Wilson
	1035-1050	Shared Decision Making in Emergency Cancer Presentation Ensure focus on type I: Highlighting the balance of diagnostic pathways, treatment options in context of emergency presentation & poor prognosis. Focussing on examples eg Lung cancer & MUO? Wales data, Mersey 90day lung data -Prognosis & transitions. Who is responsible for first 24-48hours? Illustrating the Macmillan - See it Say it workshops	Dr Ollie Minton
	1050-1110	Which patient's cohorts have a more favourable prognosis? Case examples 'favourable MUO/CUP' presenting who in AO teams shouldn't miss out in terms of escalating to oncology and not to BSC.....	Dr Claire Mitchell
	1110-1130	"That's not my patient" nursing management of the inpatient pathway	Alison Taylor
	1130-1150	Panel Q and A session	All
	1150-1155	Summary & Close	Chairs: Dr Anthony Cunliffe & Dr Caroline Wilson
09:00hrs ~ 11:55hrs	BLADDER BREAKOUT – CHAIRS: Professor Peter Hoskin – Buckingham Meeting Room		
	This session will cover a wide range of developments at the forefront of bladder cancer management including imaging, local and systemic treatments. Specific sessions will cover functional imaging, bio-adaptation and MR-guided RT, management of NMIBC and CIS beyond BCG, current and future roles of the new antibody-IO combinations and the use of brachytherapy in the management of bladder cancer. Special thanks to Professor Ananya Choudhury for designing the programme.		
	0900-0905	Welcome and introduction	Prof Peter Hoskin
	0905-0935	Systemic treatment in metastatic bladder cancer, with a focus on antibody-drug conjugates and beyond!	Dr Aspasia Soutati
	0935-0940	Panel Q and A session	All

	0940-1010	Treatments beyond BCG for NMIBC	Mr Krishna Narahari
	1010-1015	Panel Q and A session	All
	1015-1045	Functional imaging, bio-adaptation and MR-guided RT	Dr Jim Zhong
	1045-1105	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1105-1135	Bladder Brachytherapy: the ultimate bladder preservation?	Dr Katharina Brück
	1135-1140	Panel Q and A session	All
	1140-1155	Summary & Closure	Prof Peter Hoskin
09:00hrs ~ 11:45hrs	BOPA BREAKOUT – CHAIR: Emma Foreman – Edinburgh Meeting Room		
	Collaborating to Provide Equity in Care for People with Cancer. BOPA is committed to collaboration with other cancer organisations, as well as strengthening our involvement with patient and public groups. In this session you will hear from the founder of OUTpatients, the UKs leading LGBTIQ+ Cancer Charity, as well an oncology pharmacist who is an expert in the field of geriatric oncology. The stream will also outline some of the inequity in the use of immunotherapy, and how BOPA is addressing this through collaboration with the IOCN.		
	0900-0905	Welcome and introduction	Emma Foreman
	0905-0935	BOPA innovations in care Let's Communicate Cancer, Safe and effective prescribing for Trans individuals living with cancer	Emma Foreman Stewart O'Callaghan
	0935-1005	Immunotherapy	Alice Tew
	1005-1020	Panel Q&A	All
	1020-1045	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1045-1115	Inclusive care in Oncology	Vanya Slavova-Boneva
	1115-1135	Panel Q and A session	All
	1135-1145	Summary & Closure	Emma Foreman

09:00hrs ~ 11:55hrs	INFORMATION EXCHANGES BETWEEN ONCOLOGISTS AND THEIR PATIENTS: AN INTERACTIVE SESSION		
	Panellist's discuss difficult issues raised by patients with MBC. CHAIR: Professor Dame Lesley Fallowfield – Osbourne Suite		
	'Have you ever said that?': Patient's recall of their metastatic consultations with HCPs. An interactive discussion		
	0900-0905	Welcome and introduction	Prof Dame Lesley Fallowfield
	0905-0920	Didactic PPT Results from the LIMBER survey	Prof Valerie Jenkins
	0920-1100	Interactive session "Have I ever said that??"	Prof Lesley Fallowfield & Dr Marina Parton Prof Carlo Palmieri & Prof Richard Simcock
	1100-1115	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1115-1150	Helping oncologists having difficult conversations – "didactic presentation on burnout, information & support resources from charities"	Prof Dame Lesley Fallowfield & Prof Richard Simcock
	1150-1155	Summary and closure	Prof Lesley Fallowfield
09:00hrs ~ 11:55hrs	IMMUNOTHERAPY BREAKOUT – CHAIR: Professor Benjamin Fairfax – Clarence Meeting Room		
	Immunotherapy is the core treatment for multiple cancer subtypes including melanoma and of increasing utility across a wider range of tumours - thus understanding why there is large variation in patient responses is of high importance. In this session we will explore clinically relevant insights into the determinants of response to immunotherapy, allowing us potentially to stratify this treatment so as to better target patients who will benefit most. Specific topics to be covered include how novel patient imaging approaches can give insights tumour related markers of immuno-sensitivity, immunotherapy in breast cancer, insights from large datasets as to molecular determinants of immunotherapy sensitivity including patients potentially resistant to immunotherapy, and the practical implications of cell therapy for NHS practice.		
	0900-0905	Welcome and introduction	Professor Benjamin Fairfax
	0905-0930	PET imaging immune-oncology responses - labelling T cells	Professor Marco De Bruyn
	0930-0935	Panel Q and A	All
	0935-0950	Immunotherapy for TNBC: biomarkers and other translational insights	Dr Olga Isaeva (Virtual)
	0950-0955	Panel Q and A session	All
	0955-1020	Robust predictors of response to ICB (CPI), including HLA loss and immunosurveillance	Dr Robert Bentham
	1020-1025	Panel Q and A session	All

	1025-1045	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1045-1110	Germline genetic variation impacts clinical outcomes to checkpoint immunotherapy in melanoma	Professor Benjamin Fairfax
	1110-1115	Panel Q and A session	All
	1115-1135	Update on cell-based immunotherapies in solid tumours	Professor Fiona Thistlethwaite
	1135-1140	Panel Q and A session	All
	1140-1145	Panels final thoughts	Panel
	1145-1150	Summary & Closure	Professor Benjamin Fairfax
09:00hrs ~ 11:55hrs	LIVER CANCER BREAKOUT – CHAIR: Dr Claudia Fulgenzi - Sandringham Meeting Room		
	<p>Bridging the gap in primary liver cancers: from clinical trials to everyday practice</p> <p>The introduction of immunotherapy and targeted therapies, along with surgical advances, have substantially improved the clinical outcomes of patients affected by hepatocellular carcinoma and biliary tract cancers over the last few years. However, not all the patients do get the same benefit from the available options, and as more alternatives emerge, a multidisciplinary approach is gaining increasing importance in shaping individualized treatment plans. This session will focus on the discussion of the most recent advances in the medical and surgical treatments for patients affected by primary liver tumours. This will be an interactive and patient-centred session, where a panel of outstanding experts will aid the audience in comprehending how the data from clinical trials can influence the everyday clinical practice.</p>		
	0900-0905	Welcome and introduction	Dr Claudia Fulgenzi
	0905-0935	Systemic therapies for advanced HCC: current scenario and challenges	Professor Ian Chau
	0935-0940	Panel Q and A session	All
	0940-1010	Adjuvant immunotherapy in HCC: are the IMbrave050 and the EMERALD trials going to change our practice?	Dr Antonio D'Alessio
	1010-1015	Panel Q and A session	All
	1015-1045	Systemic therapies for Biliary Tract Cancers: opportunities and challenges of immunotherapy and targeted therapies	Dr Grainne O'Kane
	1045-1105	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1105-1135	Liver transplant for primary liver tumours in 2024: advancements and open issues	Mr Abdul Rahman Hakeem
	1135-1140	Panel Q and A session	All
	1140-1155	Summary & Closure	Dr Claudia Fulgenzi

09:00hrs ~ 11:55hrs	RADIOTHERAPY BREAKOUT – CHAIR: Dr Alison Tree – Balmoral Meeting Room		
	Come and find out how next-generation radiotherapy can make drug treatments work better and for longer in a range of cancer scenarios. Where could radiotherapy fit in to your patient's care? We have a world-leading group of speakers who will cover how radiotherapy can delay the need for drug treatments, can work in tandem with drug treatments to enhance response, can be used in advance disease to delay chemotherapy and can even be used again where radiotherapy has failed. Come for an update on what current and future radiotherapy techniques can offer!		
	0900-0905	Welcome and introduction	Dr Alison Tree
	0905-0935	Oligometastatic cancer a case for SBRT or systemic therapy (or both)?	Professor Piet Ost
	0935-0940	Panel Q and A session	All
	0940-1010	Radiotherapy enhances anti-tumour immune response?	Professor Kevin Harrington
	1010-1015	Panel Q and A session	All
	1015-1045	Oligo-progression: Radiotherapy reverses treatment resistance	Dr Fiona McDonald
	1045-1105	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1105-1135	When is reirradiation better than the alternatives?	Dr Rebecca Muirhead
	1135-1140	Panel Q and A session	All
	1140-1155	Summary & Closure	Dr Alison Tree
09:00hrs ~ 11:55hrs	UKONS BREAKOUT – Dr Karen Campbell - Ambassador Meeting Room		
	Nursing research has a tremendous influence on current and future professional nursing practice, consequently rendering it an essential component of the educational process. The UKONS session at UK Oncology Forum looks to bring together nurses from all levels, staff nurse to nurse consultant, to discuss how we can all use research in our day to day practice. The sessions will give delegates the opportunity to see how nursing research is developed and completed and how they can get involved in research. Research is for everyone and we hope to see nurses from all levels and backgrounds at this session.		
	0900-0905	Welcome and introduction	Dr Karen Campbell
	0905-0935	Discussing the various NIHR or other opportunities: associate PI, PCAF (including UKONS funded PCAF)	Dr Jo Bird, Naomi Clatworthy & Dr Tessa Renouf
	0935-0950	Panel Q and A session	All
	0950-1020	UKONS funded research project	Dr Karen Campbell
	1020-1050	Support for people wanting to do research: RSS, etc	Claire Pegg
	1050-1105	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	All
	1105-1135	UK ECRC	Dr Sukhdeep Kaur Nagpal

			Dr Harshani Green
	1135-1145	Panel Q and A session	All
	1145-1155	Summary & Closure	Dr Karen Campbell
09:00hrs ~ 11:50hrs	UPPER GI BREAKOUT – CHAIRS: Professor Russell Petty & Dr Janet Graham – Lancaster Meeting Room		
	<p><i>‘Optimising Multimodal Treatment of Gastroesophageal Cancers in the Curative Setting and Beyond’</i></p> <p>Much impactful topical emerging data/ pending practice change at the moment is around curative treatment setting e.g. addition of CPI to FLOT MATTERHORN and KN585 data, CPI alone in MSI, use of ctDNA to determine post-surgical treatment, and there are also a few very clinical practice relevant UK proposed trials in this space which it would be useful to publicise with UK UGI community- ZODIAC, TNT, DECIPHER, LODESTAR, GASTROSCOPE(not strictly curative but primary oncological) and we can invite the CIs to come and speak.</p>		
	0900-0905	Welcome and introduction	Prof Russell Petty
	0905-0920	ASCO update with focus on ESOPECC trial	Dr Janet Graham
	0920-0940	FLOT versus CROSS: is the debate (finally) over? - Medical oncology perspective	Dr Naureen Starling
	0940-1000	Radiation oncology perspective	Dr Sarah Gwynne
	1000-1005	Panel Q and A session	
	1005-1030	Durham Hall - Refreshment Break in Exhibition Hall (PLEASE VISIT STANDS)	
	1030-1050	Total Neoadjuvant therapy and the TNT-OAC trial	Prof Tim Underwood
	1050-1110	High dose palliative radiotherapy for inoperable gastric cancer and the GASTROSCOPE trial	Dr Sarah Gwynne
	1110-1130	Optimising chemoradiotherapy for oesophageal cancer and SCOPE3 trial	Dr Chris Jones
	1130-1145	Developing Personalised Cancer Vaccines for Gastroesophageal Adenocarcinomas and the PROTEAN trial	Prof Russell Petty
	1145-1150	Summary and closure	Prof Janet Graham
12:00hrs ~ 1300hrs	<p>CLOSING KEYNOTE SPEAKER - Professor Frederic Thomas</p> <p>Darwin the Devil and the Management of Transmissible Cancers</p> <p>Oxford Meeting Room – Main Plenary</p>		
13:00hrs ~ 14:00hrs	Lunch & refreshments in Exhibition Hall Cambridge & Durham (PLEASE VISIT STANDS)		

New Look Exhibition Hotspots

Join us in the Cambridge & Durham Exhibition Hall and be part of these engaging and interactive sessions

Thursday 13th June 2024

Time	Hotspots
12:05hrs~12:15hrs	Breaking News Cancer Vaccines (Part 1) Professor Lennard Lee NHSE
12:15hrs ~ 12:35hrs	Immersive Wellbeing and Coaching Session – set your own personal wellbeing and resilience goal today? Claire will cover this topic and take the audience through a coaching-style exercise leaving delegates to create their own personal wellbeing and resilience goal and to begin this immediately. Claire covered this topic extensively at ESMO 2023 and received excellent feedback. Professor Claire Hardy, Lancaster University
12:35hrs ~ 12:55hrs	Artificial Intelligence (AI) in cancer care: the present and the future - This interesting and fascinating talk looks at the current applications of AI in cancer care across the care pathway from primary prevention to early detection and screening, treatment and care Then moving through to end of life care, with many examples. We close by looking to the potential application of emerging large multimodal AI models- for the future of cancer care. Dr Danny Ruta, Clinical Artificial Intelligence Lead, Guy's Cancer Centre
17:30hrs ~ 17:45hrs	Perspectives on Pre-treatment Consultations (UKONs) Dr Ruth Hammond & Dr Catherine Oakley
17:45hrs ~ 18:05hrs	Artificial Intelligence (AI) in cancer care: the back to the future - This interesting and fascinating talk looks at the current applications of AI in cancer care across the care pathway from primary prevention to early detection and screening, treatment and care Then moving through to end of life care, with many examples. We close by looking to the potential application of emerging large multimodal AI models- for the future of cancer care. Dr Danny Ruta, Clinical Artificial Intelligence Lead, Guy's Cancer Centre
18:10hrs ~18:30hrs	Immersive Wellbeing and Coaching Session – set your own personal wellbeing and resilience goal today? Claire will cover this topic and take the audience through a coaching-style exercise leaving delegates to create their own personal wellbeing and resilience goal and to begin this immediately. Claire covered this topic extensively at ESMO 2023 and received excellent feedback. Professor Claire Hardy, Lancaster University

Friday 14th June 2024

Time	Hotspots
10:45hrs ~ 10:55hrs	'Talking, Telling, Sharing' framework for family-centred cancer care conversations at end of life Jeffrey Hanna
11:00hrs ~ 11:15hrs	Breaking News Cancer Vaccines (Part 2) Professor Lennard Lee NHSE
13:05hrs ~ 13:25hrs	Immersive Wellbeing and Coaching Session – set your own personal wellbeing and resilience goal today? Claire will cover this topic and take the audience through a coaching-style exercise leaving delegates to create their own personal wellbeing and resilience goal and to begin this immediately. Claire covered this topic extensively at ESMO 2023 and received excellent feedback. Professor Claire Hardy, Lancaster University
13:25hrs ~ 13:45hrs	'Talking, Telling, Sharing' framework for family-centred cancer care conversations at end of life Jeffrey Hanna
13:45hrs ~ 13:55hrs	The misery of oral complications during cancer treatment (which impacts all cancer treatments – everybody's problem) Dr Barry Quinn

Secretariat

Athena Meetings & Events

AXIS, Jordangate House

Jordangate

Macclesfield

England

SK10 1EQ

Contact Details

Sharon Poole sharon@athenameetings.com

Lisa Young lisa@athenameetings.com

Jak Poole jak@athenameetings.com